{"id":32977,"date":"2023-06-16T16:51:30","date_gmt":"2023-06-16T16:51:30","guid":{"rendered":"https:\/\/todaysveterinarypractice.com\/?p=32977"},"modified":"2023-06-16T16:56:32","modified_gmt":"2023-06-16T16:56:32","slug":"ancient-treatments-for-a-prehistoric-disease","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarypractice.com\/personal-professional-development\/ancient-treatments-for-a-prehistoric-disease\/","title":{"rendered":"Ancient Treatments for a Prehistoric Disease"},"content":{"rendered":"

Osteoarthritis can be called the oldest known disease. The first example was preserved in the spine of a 100-million-year-old Comanchean dinosaur. Around that same time, give or take a few million years, the first example of polyarthritis was saved in the remains of a Mesozoic Platecarpus<\/i>. All the joints in the left hallux of this reptile were deformed by osteoarthritis. Based on microscopic investigations of these samples, this disease has not changed its pathologic characteristics in spite of the extraordinary changes in its animal hosts during this time. It appears to be a solid, immutable part of life that is oblivious to evolution. It is a stretch then to suggest that a cure for osteoarthritis is \u201cjust around the corner,\u201d but recent advances have made significant inroads into attacking the underlying pathophysiology. In this issue, Dr. Tamara Grubb reviews some of the therapies<\/a> that have recently become available for <\/span>canine osteoarthritis<\/span>. One of the most interesting new therapies discussed is 117m<\/sup>Sn, a radioisotope of a heavy metal first used back in 3500\u00a0BC, which may now be used\u00a0as a radiosynoviorthesis agent in canine elbows and could be beneficial for up to 12 months following a single outpatient intra-articular injection. This treatment approach has been used successfully for decades in people in Europe. As its use in veterinary medicine is relatively new, it seems appropriate to be cautious about its safety and success for our patients. Read Dr.\u00a0Grubb\u2019s article to learn more about this treatment and others that show promise in improving joint function, reducing pain, and enhancing the overall quality of life for our faithful friends.<\/span><\/p>\n

\n

What We\u2019re Reading<\/span><\/h3>\n

In each issue, a member of our Editorial Advisory Board will share a recent open access publication, including their key takeaways and its practical conclusion. <\/i><\/p>\n

Effective Treatment of Canine Chronic Cutaneous Lupus Erythematosus Variants With Oclacitinib: Seven Cases
\n<\/b><\/span>Harvey RG, Olivr\u012b A, Lima T, Olivry T
\n<\/span>https:\/\/doi.org\/10.1111\/vde.13128<\/span><\/a><\/p>\n

WHAT WAS INVESTIGATED?<\/b><\/span><\/p>\n

Oclacitinib (0.4 to 0.6 mg\/kg q12h for 14 days and then q24h thereafter), a Janus kinase inhibitor, has been approved to control atopic and allergic dermatitis in dogs. Currently, no specific drugs are approved for the treatment of canine cutaneous lupus erythematosus (CLE) in humans or dogs. This off-label study investigated oral oclacitinib monotherapy as a potential treatment for 7 dogs with chronic CLE variants.<\/p>\n

WHAT WAS FOUND?<\/b><\/p>\n